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Wu et al. couple next-generation sequencing with structural analysis to illuminate the key
processes that enable the natural evolution and selection of broadly neutralizing antibodies to
HIV-1, providing a potential roadmap for the development of HIV-1 vaccine strategies to accelerate
the induction of protective antibodies.Thegenerationof broadly reactive neutral-
izing antibodies is the holy grail of HIV-1
vaccine research, but no HIV-1 vaccine
candidate has realized this goal to date.
A substantial fraction of HIV-1-infected in-
dividuals is able to induce broadly neutral-
izing antibody responses over time (Mikell
et al., 2011; Gray et al., 2011). Interest-
ingly, high viral loads and chronic antigen
exposure typically appear to contribute
to the generation of broadly neutralizing
antibodies (Piantadosi et al., 2009; Liao
et al., 2013), although some broadly
neutralizing antibodies have also been
cloned from subjects with spontaneous
control of viral replication. These anti-
bodies typically have high levels of so-
matic mutations (Burton et al., 2012;
West et al., 2014). Although the prospect
of designing a vaccine that can induce
this degree of somatic hypermutation
is daunting, understanding the natural
evolutionary path of the development of
these antibodies may provide important
clues for the generation of vaccine immu-
nogens and strategies that ultimately aim
to recapitulate this pathway.
In a tour-de-force study in this issue of
Cell, Wu et al. (2015) used next-generation
sequencing coupled with detailed struc-
tural determinations to reconstruct the
evolutionary process that led to the devel-
opment of a series of potent and broad
neutralizing antibodies directed against
the CD4 binding site in a single donor
from 1995 to 2009. Evolutionary analyses
highlight the remarkable diversity of the
VRC01 lineage, with at least six heavy-
chain lineages and five light-chain line-
ages. Interestingly, these clonal families
fell into three major clades, with up to25% intra-clade sequence divergence
and up to 50% inter-family divergence.
Each clade exhibited marked increases in
somatic hypermutation over this period of
time, suggestive of progressive evolution
over 15 years. Remarkably, all clonal fam-
ilies were represented at the earliest time
points, suggesting early selection that
continued to expand in parallel in a pro-
gressive manner over the study period.
Strikingly, new families reflecting the se-
lectionof novel germlineB cell populations
by the evolving virus did not emerge.
These data collectively point to the early
selection and progressive development
of a finite set of naive B cell families.
Despite dramatic sequence diversity
among the clades, all representative anti-
bodies from each family recognized an
almost identical footprint on the viral en-
velope, sharing up to 95% conservation
in the paratope surface. However, each
family evolved a different structural solu-
tion to reach the unusual deeply recessed
shape of this site of vulnerability on the
HIV-1 envelope, illustrating that there are
several immunologic solutions to the
same structural antigenic problem. These
results argue that the immune system har-
bors a remarkable capacity to explore a
wide landscape of solutions to neutralize
difficult epitopes. The early selection of
several germline B cells followed by
continuous evolution over a substantial
period of time may therefore be critical
for the generation of broadly neutralizing
antibody responses.
It is well known that HIV-1 mutates at a
remarkable frequency, 1.5 substitutions
per 100 nucleotides per year. Interest-
ingly, this mutation rate was surpassedCellby the evolution of the VRC01 lineage,
which incorporated 2 substitutions per
100 nucleotides per year. Thus, the hu-
moral immune response evolved more
rapidly than the virus in this individual,
suggesting a mechanism by which anti-
body lineages can achieve extraordinary
diversity in the setting of chronic HIV-1
infection (Figure 1). The mutation rates in
the evolution of other broadly neutralizing
antibodies showed even higher mutation
rates of 9 to 11 substitutions per 100 nu-
cleotides per year for the V1V2-specific
antibody CAP256 and the CD4 binding
site-specific antibody CH103. It is unclear
whether these accelerated rates of muta-
tion are attributable to higher viral loads in
the CAP256 and CH103 donors, easier to
neutralize features of the antibody para-
topes, peculiarities in the host back-
ground of the donors, or simply the fact
that these antibodies evolved within the
first year of infection under distinct inflam-
matory conditions. However, for all three
antibodies, kinetic analyses of evolu-
tionary rates suggested a trend toward
more rapid evolution of the antibody
response in early infection that slowed
during later states of infection. These
data suggest the importance of devel-
oping vaccine strategies that drive rapid
and persistent B cell selection at these
levels. Defining the key triggers that
drive accelerated somatic hypermutation,
which would allow B cells to explore
immunologic solutions more quickly and
rigorously, may therefore improve the
ability of vaccines to elicit broadly neutral-
izing antibodies to HIV-1.
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Figure 1. Relative Kinetics of the Evolution of HIV-1 and the VRC01 Antibody Lineage
The antibody lineage evolved more rapidly than the virus did in this individual, suggesting a mechanism by
which B cells can achieve extraordinary diversity in the setting of chronic HIV-1 infection.development down a particular path-
way by sequential vaccination strategies
has gained support. The evolutionary
complexity highlighted in this study, how-
ever, suggests that the design or selection
of discrete immunogens able to recapitu-
late antigen-driven B cell selection path-
ways will be challenging. Strategies that
aim to deliver persistent immunogens,
such as with the use of replicating
vectors, are therefore being explored.
Whether viral evolution is also required
to drive broadly neutralizing antibody re-
sponses remains to be determined.
Although a burst in viral diversity has
been linked to the rapid evolution of
neutralizing responses in certain cases428 Cell 161, April 23, 2015 ª2015 Elsevier In(Liao et al., 2013), some broadly neutral-
izing antibodies have been isolated from
subjects that exhibit spontaneous control
of viral replication and therefore reduced
viral diversity.
Several unanswered question remain.
One key question is whether similar de-
grees of evolutionary complexity are
required for the development of broadly
neutralizing antibodies against other
key targets, such as the V2 or V3 glycan-
dependent epitopes, the membrane-
proximal external region, and the gp120-
gp41 binding interface. Another important
question is whether triggers that drive
accelerated somatic hypermutation can
be defined and utilized to allow vaccine-c.elicited B cells to explore immunologic
solutions more rapidly. Overall, the pre-
sent studies chart the development of
CD4 binding site antibodies in a remark-
able level of detail, providing insights
into the plasticity of the immune response
and the path to the generation of broadly
neutralizing antibodies.REFERENCES
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